For Patients and Families

NANT: Your resource to understanding Neuroblastoma

The NANT consortium is a group of 15 Universities and Childrens Hospitals with strong research and treatment programs for neuroblastoma. Working closely together, they test promising new therapies for high-risk and relapsed neuroblastoma. The majority of funding for NANT comes from the National Cancer Institute.

NANT was formed to provide a group of closely collaborating investigators who are linked with laboratory programs developing novel therapies for high-risk neuroblastoma. NANT conducts clinical trials that test new drugs and new combinations of drugs against high-risk neuroblastoma. Those with promising results will then be considered for more extensive national testing.